Fate Therapeutics, Inc. (FATE) vs Inhibikase Therapeutics, Inc. (IKT)
A side-by-side comparison of Fate Therapeutics, Inc. and Inhibikase Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FATE
Fate Therapeutics, Inc.
$2.38HealthcareDelayed quote: Oct 6, 2026, 11:10 AM EDT
IKT
Inhibikase Therapeutics, Inc.
$1.99HealthcareDelayed quote: Oct 6, 2026, 11:09 AM EDT
Total return — FATE vs IKT
growth of $100 · dividends reinvested · last 6yFATE -97.6% (-46.3%/yr)IKT -96.6% (-43.2%/yr)IKT compounded faster over this window
FATE IKT
FATE vs IKT: by the numbers
- •FATE is the larger company ($277M vs $262M market cap).
- •Both run net losses; IKT's is the smaller (0.00% vs -1941.09% net margin).
Metrics side by side
Valuation
| Metric | FATE | IKT |
|---|---|---|
| P/S ratio | 42.65 | N/A |
| P/B ratio | 1.80 | 1.71 |
Profitability
| Metric | FATE | IKT |
|---|---|---|
| Gross margin | -94.12% | 0.00% |
| Operating margin | -2222.45% | 0.00% |
| Net margin | -1941.09% | 0.00% |
| ROE | -82.12% | -39.55% |
| ROIC | -58.72% | -42.92% |
Growth (annualized)
| Metric | FATE | IKT |
|---|---|---|
| Revenue CAGR (5Y) | -32.98% | N/A |
| Total return CAGR (5Y) | -46.86% | -29.10% |
Frequently asked
- How have FATE and IKT total returns compared?
- Over the past 5 years, FATE delivered -46.86% and IKT delivered -29.10% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.